1012-1013 / 2953
SABR in stage I histologically proven NSCLC: an Italian
multicenter observational study
1,0
0,8
0,6
2B
OVERALL SURVIVAL
Time since enrollement (months)
96,00
84,00
72,00
60,00
48,00
36,00
24,00
12,00
,00
0,4
0,2
0,0
Number at risk
196 165 107 63 37 15 7 4 1
OVERALL SURVIVAL
% 1 year:
94.0
% 2 years:
81.6
% 3 years:
68.0
Ricardi et al, Lung Cancer 2014